CymaBay Therapeutics, Inc.
Combination treatment of NAFLD and NASH
Last updated:
Abstract:
Combination treatment of NAFLD, including NASH, with seladelpar or a salt thereof and a glucagon-like peptide-1 (GLP-1) receptor agonist.
Status:
Application
Type:
Utility
Filling date:
13 Nov 2019
Issue date:
21 May 2020